These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 18207634)

  • 1. Botulinum toxin a era: little steps towards a better understanding.
    Del Popolo G
    Eur Urol; 2008 Jul; 54(1):25-7. PubMed ID: 18207634
    [No Abstract]   [Full Text] [Related]  

  • 2. Intradetrusor botulinum toxin injections for neurogenic overactive bladder: are we there yet?
    Lemack GE
    Eur Urol; 2008 Feb; 53(2):240-1. PubMed ID: 17997019
    [No Abstract]   [Full Text] [Related]  

  • 3. What is the optimum dose of type a botulinum toxin for treating neurogenic bladder overactivity?
    Shah J; Patki P; Patil K; Wood S
    BJU Int; 2006 Aug; 98(2):466-7. PubMed ID: 16879701
    [No Abstract]   [Full Text] [Related]  

  • 4. Editorial comment on: Six-year follow-up of botulinum toxin A intradetrusorial injections in patients with refractory neurogenic detrusor overactivity: clinical and urodynamic results.
    Schurch B
    Eur Urol; 2009 Mar; 55(3):711-2. PubMed ID: 18814956
    [No Abstract]   [Full Text] [Related]  

  • 5. Editorial comment on: Six-year follow-up of botulinum toxin A intradetrusorial injections in patients with refractory neurogenic detrusor overactivity: clinical and urodynamic results.
    Fowler CJ
    Eur Urol; 2009 Mar; 55(3):712. PubMed ID: 18814958
    [No Abstract]   [Full Text] [Related]  

  • 6. Editorial comment on: Botulinum toxin A detrusor injections in patients with neurogenic detrusor overactivity significantly decrease the incidence of symptomatic urinary tract infections.
    Novara G
    Eur Urol; 2008 Mar; 53(3):618-9. PubMed ID: 17804151
    [No Abstract]   [Full Text] [Related]  

  • 7. Editorial comment on: histological changes in the urothelium and suburothelium of human overactive bladder following intradetrusor injections of botulinum neurotoxin type A for the treatment of neurogenic or idiopathic detrusor overactivity.
    Haferkamp A
    Eur Urol; 2008 Jun; 53(6):1253. PubMed ID: 18343561
    [No Abstract]   [Full Text] [Related]  

  • 8. Editorial comment.
    Greenfield SP
    Urology; 2010 Jul; 76(1):231; author reply 231. PubMed ID: 20599118
    [No Abstract]   [Full Text] [Related]  

  • 9. A prospective study to evaluate the safety, tolerability, efficacy and durability of response of intravesical injection of botulinum toxin type A into detrusor muscle in patients with refractory idiopathic detrusor overactivity.
    Sahai A
    BJU Int; 2006 Feb; 97(2):413. PubMed ID: 16430657
    [No Abstract]   [Full Text] [Related]  

  • 10. Editorial comment.
    Bologna R
    Urology; 2010 Jul; 76(1):231-2; author reply 232. PubMed ID: 20599119
    [No Abstract]   [Full Text] [Related]  

  • 11. Botulinum toxin A-when is a unit not a unit?
    Harper L
    J Urol; 2009 Jan; 181(1):414; discussion 414-5. PubMed ID: 19019386
    [No Abstract]   [Full Text] [Related]  

  • 12. Injection of botulinum toxin type A in the urethral sphincter to treat lower urinary tract dysfunction: a review of indications, techniques and results.
    Karsenty G; Baazeem A; Elzayat E; Corcos J
    Can J Urol; 2006 Apr; 13(2):3027-33. PubMed ID: 16672114
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Re: Karsenty G, Reitz A, Lindemann G, et al. Persistence of therapeutic effect after repeated injections of botulinum toxin type A to treat incontinence due to neurogenic detrusor overactivity (Urology 68:1193-1197, 2006).
    Kadi N
    Urology; 2008 Oct; 72(4):951-2. PubMed ID: 18926254
    [No Abstract]   [Full Text] [Related]  

  • 14. [Prospective study of the clinical and urodynamic results of intradetrusor botulinum toxin injections for the treatment of neurogenic overactive bladder].
    Bentaleb Y; Castel-Lacanal E; Sallusto F; De Boissezon X; Malavaud B; Marque P; Rischmann P; Gamé X
    Prog Urol; 2008 Jul; 18(7):449-55. PubMed ID: 18602606
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A minimally invasive technique for outpatient local anaesthetic administration of intradetrusor botulinum toxin in intractable detrusor overactivity.
    Schulte-Baukloh H; Knispel HH
    BJU Int; 2005 Feb; 95(3):454. PubMed ID: 15679820
    [No Abstract]   [Full Text] [Related]  

  • 16. Six-year follow-up of botulinum toxin A intradetrusorial injections in patients with refractory neurogenic detrusor overactivity: clinical and urodynamic results.
    Giannantoni A; Mearini E; Del Zingaro M; Porena M
    Eur Urol; 2009 Mar; 55(3):705-11. PubMed ID: 18814955
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A simplified technique for botulinum toxin injections in children with neurogenic bladder.
    Pascali MP; Mosiello G; Marciano A; Capitanucci ML; Zaccara AM; De Gennaro M
    J Urol; 2011 Jun; 185(6 Suppl):2558-62. PubMed ID: 21527204
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Criteria and best clinical practice guidelines for first intradetrusor injection of botulinum toxin type A to treat neurogenic detrusor overactivity].
    Perrouin-Verbe B; Ruffion A; Gamé X; Denys P; Kerdraon J; Karsenty G; de Sèze M; Haab F; Saussine C; Soler JM; Amarenco G; Chartier-Kastler E
    Prog Urol; 2009 Jun; 19(6):372-82. PubMed ID: 19467455
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of neurogenic incontinence with botulinum toxin A.
    Schurch B; Schmid DM; Stöhrer M
    N Engl J Med; 2000 Mar; 342(9):665. PubMed ID: 10702067
    [No Abstract]   [Full Text] [Related]  

  • 20. Therapeutic satisfaction and dissatisfaction in patients with spinal cord lesions and detrusor sphincter dyssynergia who received detrusor botulinum toxin a injection.
    Kuo HC
    Urology; 2008 Nov; 72(5):1056-60. PubMed ID: 18533231
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.